Filing Analysis
Adagio Medical Holdings announced positive pivotal clinical trial results for its vCLAS® Ventricular Ablation System on April 26, 2026. The disclosure was made via a press release filed under Item 8.01 of Form 8-K.
Key Facts
- Announcement of positive pivotal results for vCLAS® Ventricular Ablation System on April 26, 2026
- The company is an emerging growth company as defined by the SEC
- The filing includes Exhibit 99.1, the full press release text
- The report was signed by Deborah Kaster, CFO and Chief Business Officer
Adagio Medical Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 16, 2026. The filing establishes the record date and the deadlines for stockholders to submit director nominations or other proposals.
Key Facts
- The 2026 Annual Meeting of Stockholders is set for June 16, 2026.
- The record date for stockholders entitled to vote is April 24, 2026.
- Stockholder proposals for inclusion in proxy materials (Rule 14a-8) must be received by April 30, 2026.
- Director nominations and other proposals under the Company's Bylaws must be submitted by April 30, 2026.
- Notice for director nominees under the SEC's universal proxy rules (Rule 14a-19) is due by April 30, 2026.
Adagio Medical Holdings announced it has received Investigational Device Exemption (IDE) approval from the FDA for its next-generation vCLAS™ Ventricular Ablation System. This regulatory milestone allows the company to commence clinical investigations of the device in the United States.
Key Facts
- FDA IDE approval received on April 8, 2026
- The approval pertains to the vCLAS™ Ventricular Ablation System
- The announcement was made via a press release titled 'Adagio Medical Receives IDE Approval from the FDA to Investigate the Next-Generation vCLAS™ Ventricular Ablation System'
- The filing was made under Item 8.01 (Other Events)
Adagio Medical Holdings, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, via a press release on March 26, 2026.
Key Facts
- The filing reports financial results for the fiscal year and quarter ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was furnished as Exhibit 99.1.
- The report date is March 26, 2026.